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ABSTRACT 
All cells in the human body contains the same genome. Yet, there are hundreds of different 
cell types, with widely different phenotype, and function. The differential gene expression 
leading to this diversity is tightly regulated by epigenetics, i.e. modifications to the genome 
without interfering with the sequence. There are a number of epigenetic modifications. In this 
thesis, I have studied DNA methylation as a readout for lineage specificity or effector 
function in cells from the immune system, in clinical settings. 
In paper I we develop a method based on DNA methylation analysis to determine the lineage 
commitment of the CD4
+
 T helper cells. First, we establish a regulatory site in the promotor 
of the IL17A gene. Next, we use signature genes IFNG, IL13, IL17A and FOXP3, to 
determine lineage commitment towards corresponding T helper cell subsets Th1, Th2, Th17 
and Tregs. We call this method EILA (Epigenetic immune lineage assay), and demonstrate 
that it is usable in clinical samples from rheumatoid arthritis and multiple sclerosis. 
In paper II, we take advantage of the same CD4
+
 T cell specific loci to investigate the 
adaptive immune response in and around the tumour microenvironment in specimens derived 
from patients with urinary bladder cancer (UBC). By sorting and examining CD4
+
 T cells 
from blood, tumour and regional lymph nodes, we conclude that patients with higher degree 
of lineage commitment have a better prognosis. Furthermore, we demonstrate that patients 
responding to neoadjuvant chemotherapy have a larger proportion of commitment cells, post 
treatment, compared with the non-responders. 
In paper III we further examine the same patient material from UBC patients, but instead 
focus on the cytotoxic features of CD8
+
 T lymphocytes. We establish a methylation pattern in 
the perforin gene PRF1 predictive for protein expression and deploy this locus as a readout 
for cytotoxic functionality. We demonstrate that the tumour infiltrating CD8
+
 T cells are pre-
dispositioned to be cytotoxic through PRF1 demethylation, but that they lack corresponding 
protein expression, and show signs of exhaustion. The cells demonstrating a TRM phenotype, 
can still be woken anew, upon in vitro re-stimulation, demonstrating that they are not 
terminally exhausted. 
In paper IV we investigate whole blood leucocytes and the DNA methylation status of the 
glucocorticoid gene NR3C1. In contrast to literature studies on healthy volunteers, our cohort 
of surgical patients demonstrate a homogeneous pattern of demethylation in the previously 
described CpG island of NR3C1. As opposed to our hypothesis, we found no correlation 
between methylation and clinical outcome post-surgery in this patient cohort. Nevertheless, 
when employing multifactorial analysis to investigating the impact of genotype we found 
four single nucleotide polymorphisms that influenced the outcome. 
In conclusion, this thesis demonstrate multiple ways in which DNA methylation analysis can 
be used to read the immune system, but also that the loci selected for investigation has to be 
carefully chosen following thorough functional investigations. The results presented herein 
can contribute to further development of treatments to a variety of clinical conditions. 
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1 INTRODUCTION 
1.1 EPIGENETICS 
Every (somatic) cell in the human body contains the same DNA, yet the diversity of cell 
types, tissues and structures is enormous. This is conducted through a tight regulation of the 
genome, so that only certain genes are expressed in a specific cell, at a certain time point, 
leading to its individual properties. The regulation is accomplished by epigenetic 
modifications, which include histone modifications and DNA methylation, among others. 
Epigenetic modifications are heritable traits that do not change the nucleotide sequence. 
Whereas histone modifications determine the accessibility of the chromatin by controlling the 
unwinding of the DNA helix to increase or decrease the steric accessibility of the nucleotide 
sequence [1], DNA methylation regulates gene expression by fine-tuning the expression 
(Figure 1). In the work within this thesis we have used DNA methylation at specifically 
selected loci to determine the phenotypic stability of immune cells. 
 
 
Figure 1. A popular scientific picture conveying a simplified version of the general idea of 
epigenetics. The book represents the whole genome. The yellow tags would be the open 
histone marks, enabling access to the region. Every page presents the DNA sequence. DNA 
methylation sites are bold, and CpG islands are highlighted within the sequence. 
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1.1.1 DNA methylation 
DNA methylation in human cells occurs almost exclusively at CpG sites, i.e. at a cytosine (C) 
residue that is followed by a guanine (G). CpG sites occur in diverse frequencies along the 
genome, and when multiple CpGs are situated in close proximity to one another, it is 
considered a CpG island. The definition of CpG island differs, but is based on the ratio 
between expected and observed C and G content, where the ratio should be between (0.4 and 
0.7). These islands often harbour regulatory features, including binding sites for transcription 
factors and other regulatory proteins, as well as being involved in three-dimensional 
formations of the chromatin [2]. De novo DNA methylation is conducted by DNA 
methyltransferases (DNMTs) DNMT3A and B, whereas DNMT1 in responsible for 
maintenance of methylation to daughter cells during replication [3]. Demethylation can occur 
both through passive demethylation during replication and by active demethylation initiated 
by TET-enzymes [4-6]. 
DNA methylation has proven to be of outermost importance during embryogenesis and cell 
lineage differentiation [7] and the impact of dysregulation has been demonstrated both during 
development and in a vast number of diseases [8-11]. Furthermore, locus specific DNA 
methylation has been investigated in a number of different cell types, in order to scrutinize 
both methylation signatures of cells at different stages, as well as its association with 
dysregulation in different clinical disease phenotypes and abnormalities [12]. 
It has become increasingly evident that our “genes are not our destiny” and that there are 
other mechanisms connecting genetics with the environment. This is obvious, when 
comparing monozygotic twins, since although genetically identical, they become gradually 
more different throughout life. The concordance rate of multifactorial diseases, including 
autoimmune diseases and cancer, is ≠1, leaving the difference gap to be explained by other 
means [13-15]. This phenomenon can, at least in part be explained by epigenetic changes. 
Thus, the era of epigenetic studies in health and disease has just begun. 
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1.2 THE IMMUNE SYSTEM 
The human body has exquisite ways to protect itself from dangers, external as well as 
internal. The immune system functions as an army that patrols the body to detect pathogens 
and abnormalities harmful to our health. The two parts of the immune system, innate and 
adaptive, work in synergy to mount the most appropriate response to the encountered threat. 
The innate arm is rapid, robust and rough, but is restricted to recognition of a few, common 
antigens, shared by many microbes and pathogens. The adaptive immune system, though 
considerably slower, has the capacity to mount an antigen specific response and allows for 
long term memory [16]. 
Inflammation has since the days of Celsus (the first century AD) been described by five 
hallmarks: tumour (swelling), rubor (redness) dolor (pain), calor (heat) and function laesa 
(loss of function), where ≥3 of these symptoms would be sufficient for diagnosis [17]. 
Although 2000 years of research has revealed the underlying complicated mechanisms, the 
physiological features still holds true. 
In this thesis I have explored different parts of the immune system, to investigate the 
possibility of using DNA methylation at specific loci as readouts of immune responses. This 
chapter will focus on the parts of the immune systems that I have explored, in the clinical 
settings I have investigated and leave out vast parts of the immune system, and its functions 
in the healthy and diseased human body. 
1.2.1 Innate immunity 
The innate branch of the immune system is the body’s first line of defence. Beyond the skin, 
and other epithelial barriers, there is a soluble defence system present in extracellular body 
fluids. It consists of enzymes and other peptides that can destroy microbes immediately upon 
contact. Part of this response is called the complement system. It involves a series of proteins 
present in the plasma and on the surface of haematopoietic cells. Simplified, the complement 
system is triggered by foreign surface structures and immune complexes and subsequently 
initiates an enzymatic cascade of reactions leading to a pore formation and consequent lysis 
of the foreign cell. In addition, the complement also facilitates phagocytosis of microbes by 
macrophages, granulocytes and dendritic cells, the key cells of the innate immune response. 
The cells belonging to the innate immune response express a variety of different receptors, 
recognizing common molecules expressed on pathogens. These molecules, collectively called 
pathogen-associated molecular patterns (PAMPs) include peptides, polysaccharides and 
nucleotide chains. The receptors are collectively called pattern recognition receptors (PPRs), 
and upon encounter of these molecular foreign patterns the receptor-bearing cell is activated 
and start to produce inflammatory cytokines and phagocytose the intruding pathogen. 
Phagocytosis has two major purposes: to degrade and eliminate the microbe, and to process 
the foreign material into peptides suitable for antigen presentation to the adaptive immune 
system [18]. 
Together, the parts of if the innate immune response protects the body in a rapid and robust, 
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although non-specific way. The link between innate and adaptive (i.e. specific) immune 
response is the antigen presenting cells (APCs), relocating to secondary lymphoid organs to 
engage lymphocytes. 
Inflammation is initiated at the moment when innate cells are activated by a danger signal, as 
described above. This will lead to accumulation of fluids through vasodilation and capillary 
leakages (swelling, reddening and pain). These fluids harbours inflammatory proteins (e.g. 
chemokines) that both act locally, but also function as chemoattractants to recruit immune 
cells. Through the combination of these events, inflammation itself affects the tissue in a way 
to further fortify the sense of pain, which in itself makes impaired functionality, to variable 
extents. When the cause of the inflammatory reaction is cleared, the inflammation has to be 
resolved and tissue damage repaired. This is mediated by feed-back signalling by already 
engaged neutrophils, and recruitment of resolution-phase macrophages, a process is described 
in detail by Ortega-Gomez et al [19]. Sufficient resolution is key to restoration of healthy, 
functional tissue. Failure in revoking the inflammation can lead to scarring, tissue damage 
and pathological states. 
1.2.1.1 STERILE INFLAMMATION 
Sterile inflammation is defined by inflammation that occurs without any non-self agent 
present. This could occur in acute situations, including trauma or major surgery of large 
tissue areas or reperfusion of ischemic tissue. It can also occur as a result of chronic 
conditions such as chronic arthritis and asbestosis [20, 21]. Despite lack of foreign molecules, 
the inflammation is triggered by endogenous structures. One of the main reasons for this is 
cell death through necrosis, as opposed to apoptosis. Necrosis is an uncontrolled way of cell-
death leading to leakage of otherwise contained molecules. This includes intracellular and 
intranuclear molecules and mitochondrial contents. In addition to intracellular molecules, 
tissue damage also induces degradation of extracellular molecules and structures. All these 
endogenous inflammation triggers are collectively termed damage associated molecular 
patterns (DAMPs). DAMPs can consequently trigger sterile inflammation [22]. Like with any 
inflammation, resolution, as mentioned above, has to ensue, or immunopathology will follow. 
In the case of acute systemic inflammation, the situation can be greater than the body can 
manage. Subsequently, an inflammatory storm that is impossible to revoke, may lead to 
system failure and death. In clinical settings, administration of glucocorticoids pre- and post-
surgery is the main line of treatment. 
1.2.1.2 GLUCOCORTICOIDS IN INFLAMMATION 
Glucocorticoids (GCs) are expressed by the adrenal gland and belong to the endocrine system 
HPA (hypothalamus, pituitary adrenal) axis. GC binds to the glucocorticoid receptor (GR), 
which is expressed in almost all cells in the human body. GR has a classic structure of a 
nuclear receptor, featuring an amino-terminal domain, a DNA binding domain and a ligand 
binding domain. It is encoded by the gene NR3C1. This gene has multiple isoforms, both 
transcriptional and translational. The regulation and function of these are not yet fully 
understood, but studies conducted mainly in the neurobehavioral field have demonstrated 
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implications in neuropsychological conditions [23]. GC affects many biological systems, but 
for the sake of this thesis, only the effects on inflammation and the immune system are 
described. 
GC is soluble and inactive in the circulation. It diffuses through cell membranes and can bind 
to the GR in the cytoplasm. Once bound, GC/GR complex can either interact with 
cytoplasmic proteins and mitochondria, or translocate into the nucleus. Once there, the 
GC/GR complex acts to directly or indirectly modulate gene expression. 
When inflammation is initiated, glucocorticoids reduce the inflammatory cytokine releases 
and dampens the signalling of PAMPs and DAMPs. This decreases the signalling and 
recruitment of the adaptive immune response. During the course of inflammation GC further 
inhibit the adaptive immune system, both by inhibiting the expression of extravasation 
receptors, which hinders the tissue re-localisation of lymphocytes to the inflamed area, but 
also through decreased chemokine expression. Once the triggering agent is cleared, GC 
facilitates the resolution by enhancing the differentiation of macrophages to become more 
efficient in clearance of apoptotic cell debris and secretion of anti-inflammatory cytokines. 
By contrast, GC disturbs processes of tissue healing. This is contradictory, as is most data 
concerning GC signalling, and the effect of GCs seems to be dose-dependent [24]. 
Glucocorticoids can also modulate the skewing of the T helper cell pool, promoting Th2 and 
Treg differentiation, but inhibiting Th1 and Th17. GCs play a role in the interface between 
APCs and T cells where GR signalling interferes with MHC expression as well as other 
receptors necessary for T cell co-stimulation. The role of GCs in inflammation is reviewed in 
detail by Cain et al. [24]. 
 
1.2.2 Adaptive immunity 
When inflammation is not sufficiently taken care of by the immediate response of the innate 
immunity, APCs migrate to secondary lymphoid organs, such as lymph nodes, where they 
present processed antigens to lymphocytes. Lymphocytes are key players of the adaptive 
immune system. The common lymphoid progenitor cells from the bone marrow give rise to a 
number of immune cells, including T and B lymphocytes. B cells are masters of the humoral 
response, creating antigen specific antibodies to target extracellular and soluble pathogens 
encountered. T cells recognize antigens presented on a major histocompatibility complex 
(MHC) molecule, situated on all nucleated cells, including antigen presenting cells [18]. 
1.2.2.1 T LYMPHOCYTES 
There are two types of T cells; CD8
+
 Cytotoxic T lymphocytes, which respond to intracellular 
pathogens such as viruses and tumour cells, and CD4
+
 T helper cells that direct the immune 
system into a humoral or a cellular response [16]. 
1.2.2.1.1 Development and maturation 
T cell maturation occurs in the thymus, a highly organised process where immature 
thymocytes are selected upon their successful T cell receptor (TCR) and their specificity. 
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This is done in two steps. First, thymocytes carrying a TCR that adequately recognize a MHC 
molecule are positively selected. The cells recognizing MHC class II will become CD4
+
 T 
helper cells, whereas the T cells carrying a TCR recognizing MHC class I will become CD8
+
 
cytotoxic T cells. The second step, negative selection, is conducted in the medulla to ensure 
that the TCR does not recognize self-antigens, which could then contribute to autoimmunity. 
Thus, thymocytes expressing a TCR that recognize a self-peptide presented by MHC 
expressed on thymic medullary epithelial cells with high affinity is eliminated to avoid self-
recognition and autoimmunity. Only a few percent of T cells undergoing this selection 
survive these two selection steps. The T cell receptor is highly variable, with 10x10
15
 possible 
variants of TCR specificity. This is conceived by genetic recombination of the V, D and J 
segment of the TCR locus during maturation in the thymus. This process, called somatic VDJ 
recombination, is unique to lymphocytes and establish the high diversity of pathogens that the 
adaptive immune system can recognize [25]. CD4
+
 Natural T regulatory cells (nTregs) (also 
called thymic derived T regulatory cells; tTregs) are a subpopulation of T cells that are 
separately developed in the thymus. Their role, simplified, is to restrain immune responses at 
the right time to modulate the intensity of inflammation. They are developed through the 
same positive and negative selection as the other Th cells, but develop into Tregs if they 
encounter medium affinity self-peptides. This is to be able to suppress the immune system 
from attacking self-antigens [26]. The master regulator and phenotype inducer of nTregs is 
the transcription factor FOXP3. The nTreg can be distinguished from peripheral T cells with 
induced FOXP3 expression by their demethylated pattern in the FOXP3 gene [27]. This 
demethylation is an active process that takes place already in the thymus, thus determining 
the lineage commitment of the nTregs [28]. After passing through thymic selection T cells 
migrate to the periphery as naïve T cells. 
1.2.2.1.2 T cell activation, circulation and memory formation 
In the human body, T cells encounter antigens through presentation by the human leucocyte 
antigen (HLA) encoded by the major histocompatibility complex (MHC). Nucleated cells in 
the body express HLA class I, which present endogenous peptides to be inspected by the 
immune system. This to ensure that “all is well”. If a cell is infected, the pathogen derived 
peptides are processed and presented, enabling antigen presenting cells (APCs) and CD8
+
 T 
cells to recognize and act towards the infection [16]. 
HLA class II is expressed on APCs (dendritic cells, macrophages, monocytes, and B cells). 
APCs capture the antigen at the site of infection and migrate to the lymph node where the 
pathogenic peptides are presented on HLA I and II molecule to the T cell for recognition by 
the TCR. Upon APC migration maturation also occurs, where the APC adapts its features to 
the infecting pathogen as well as the inflammatory environment at the infectious site [18]. 
Depending on the environmental signals present upon T cell activation, as well as the co-
stimulatory molecules expressed by the APC, a diverse range of effector and memory cells 
are formed [29]. 
Activation of lymphocytes requires tree signals for proper initiation; TCR-HLA recognition, 
binding of co-stimulatory molecules and immune-stimulatory environment (cytokines). When 
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activated, T cells mature into different phenotypes, both in terms of immunological directions 
and memory traits. The memory formation, in brief, constitutes of several properties, where 
tissue localisation and activation states are the major features. Thus, the cells are subdivided 
into the recirculating phenotypes; effector memory T cells (TEM) and central memory T cell 
(TCM), which are further distinguished by their ability to enter peripheral tissue or stay in 
blood- and lymphatic circulation, respectively. Contrary to these subsets are the tissue 
resident memory T cells (TRM), which resides in the tissue, without possibility to re-enter the 
circulation. The partitioning of these memory subsets is, however, not rock solid [29]. 
Simultaneously, activated T cells differentiate in terms of immunological pathways, where 
there are several distinct routs depending on the pathogen encountered. Simplified, these can 
be divided into three types of immunity, depicted in figure 6 (page 26) [30, 31]. 
In the light of this, here follows a brief description of the CD4
+
 and CD8
+
 T lymphocytes 
investigated within this thesis, and their role in immunity. 
1.2.2.1.3 CD4+ T helper lymphocytes 
The role of the T helper cell (Th) is to direct the subsequent immune response into an 
adequate attack depending on the nature of the pathogen/danger signal. This is conducted 
through lineage commitment during Th cell activation. Dysregulation of this process may 
lead to inadequate immune responses and cause disease, such as failure to distinguish 
pathogens, but also to autoimmune disease, allergy and cancer. 
The naïve T helper cell will proliferate to become one out of several potential subpopulations 
of mature T helper effector cells, thereby directing the subsequent immune responses [16]. 
There are a number of different T helper cell lineages known to date, and during recent years 
more have been discovered. The most pronounced are T helper 1 (Th1), T helper 2 (Th2) and 
T helper 17 (Th17), as well as the thymic derived natural T regulatory cell (described above). 
In addition, there are more recently discovered lineages denoted Th9, Th22 and T follicular 
helper cells (Tfh cells) [32]. These are not within the scoop of this thesis. The subset that is 
established during activation and maturation acquire a number of signature features, in order 
to steer the subsequent immune response towards different paths. The two distinct branches 
are the cytotoxic response, featuring recruitment and activation of cytotoxic T cells, 
phagocytes and NK cells, and the humoral response, recruiting B lymphocytes as the key 
player [16]. 
All of the cell-cell interactions described above are through highly specific antigen 
recognition receptors (TCR, BCR, MHC), why this is called the specific immune system 
[33]. 
Here follows a short description of the T helper cell subsets and their signature features, such 
as master transcription factors, cytokine production and known epigenetic regulation, with 
emphasis on the human setting. 
1.2.2.1.3.1  Th1 cells  
Th1 lymphocytes are known to be the regulators of cellular immunity, i.e. activation of CD8
+
 
cytotoxic lymphocytes and enhancement of antigen presentation. The signature master 
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transcription factor (TF) T-bet collaborates with signal transducer and activator of 
transcription 1 (STAT1) and STAT4 to establish the expression of Th1 signature cytokine 
interferon-γ (IFNγ) [34]. Epigenetic studies performed in mice show permissive histone 
marks (H3K4me3) at the Ifng locus in Th1 cells specifically, whereas this site in naïve, Th2, 
Th17 and Tregs is repressed (H3K27me3) [35]. Consistently there are regulatory methylation 
patterns of the same locus in the corresponding human cells, where Th1 are demethylated and 
the other three lineages, and naïve cells are hypermethylated [36]. The master regulator T-bet 
show a more ambiguous pattern in mice, with both repressive and permissive histone patterns 
[35]. 
1.2.2.1.3.2  Th2 cells  
The humoral response is initiated by Th2 cells when presented with antigens of extracellular 
pathogens and toxins. Upon stimulation, STAT6 and extrinsic interleukin (IL) 4 induce 
GATA3 expression that leads to production of signature cytokines IL-4 and IL-13 [34]. 
Similar to the Th1 setting, the master TF of Th2, Gata3, show both permissive and repressive 
histone marks in mice [35], while Il4 is exclusively open in the Th2 setting. In humans, a 
number of studies have been conducted on the Th2 locus (IL-4, IL-13 and IL-5). Although it 
is not as uniform as in the IFNG locus, there are some differentially methylated CpG sites in 
Th2 cytokine locus that distinguish them from Th1/Th17/Treg/naïve cells [37, 38]. 
1.2.2.1.3.3  Th17 cells  
T helper 17 cells play a role in the defence against helminths, fungi and extracellular bacteria 
[39], and have also been implicated in a number of autoimmune diseases as well as in tumour 
immunology [40]. It is of importance to notice the numerous differences between human and 
mouse generation of Th17 cells when reviewing the literature. In the human setting, 
transforming growth factor-β (TGFβ), together with IL-1β, (IL-6) and STAT3-inducing 
cytokines IL-21 and IL-23 elicit RORγt, the master transcription factor of Th17 cells, leading 
to the expression of IL-17. Epigenetically, Th17 cells have a demethylated pattern in IL17A 
locus and RORyt gene RORC2 in human [41, 42] as well as permissive histone marks in 
mouse both restricted to this subset. Rorc locus also show a somewhat more lineage specific 
histone pattern than the master TFs of the other subset [35]. 
1.2.2.1.3.4  Natural T regulatory cells  
As described above, natural Tregs are developed already in the thymus, and are therefore not 
properly belonging to the T helper cell pool. In humans these thymus derived cells are 
considered to be the only stable regulatory cells, even though other subset can express the 
master TF FOXP3 and exert regulatory functions. Unlike the nTregs, the FOXP3 expression 
by activated Th cells are transient, and doesn’t seem to lead to acquisition of suppressive 
function, but rather have a self-limitation to control activation [43]. It has been shown that a 
way of distinguishing human nTregs from induced FOXP3-expressing Tregs is by the 
methylation pattern on the FOXP3 locus. Only nTregs show a demethylated pattern, allowing 
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a stable expression [27]. In mice the permissive histone marks are also more restricted for 
Foxp3 than some of the aforementioned TFs [35]. 
1.2.2.1.3.5  Lineage plasticity  
The potential flexibility between the subsets is of vast interest due to possibilities to 
manipulate immune responses in a therapeutic manner towards various diseases. Current 
ongoing discussions on flexibility in-between lineages includes hypothesis on variation of 
intensity during primary TCR stimuli [44-46], accessibility of chromatin by master 
regulators, transcription factors and earlier factors [47, 48] as well as the impact on cytokine 
milieu during activation. However research in this field often lack discrimination between 
human and murine settings, a fact that might have immense impact [49, 50]. 
The stability and plasticity in-between these different lineages have been a subject for debate 
for more than two decades. Firstly, transitions between i.e. Th1 and Th2 was explored 
showing that time and repeated stimulus decrease the ability to switch lineage commitment 
[51-53]. More recently, the flexibility in-between Th1 and Th17 cells have been investigated, 
due to numerous reports on IFNγ/IL-17 double positive cells [42, 54]. These studies suggest 
partial flexibility and epigenetic modulation from Th17 cells to a subset called non-classic 
Th1 cells. It becomes obvious when reviewing the multiple lineages that the STAT family 
plays a crucial role in differentiation of these subpopulations. Numerous studies on this 
protein family in the context of Th cell regulations have been conducted [55] and it is clear 
that STATs affects both positive and negative regulation of transcription as well as the 
epigenetic landscape in T helper cells [56]. Genome-wide investigations of histone marks in a 
number of Th cells have been performed, revealing a much more multifaceted pattern then 
assumed [35]. Simplified, open patterns were revealed on the signature cytokines for every 
subset investigated, respectively, but when investigating histone methylations at loci of 
signature transcription factor a bivalent pattern occurred, insinuating a more flexible 
arrangement. Although it is worth keeping in mind that these studies were performed on 
murine, in vitro obtained subpopulations, examined at one single time point, it might shed 
some light on the complexity of the plasticity matter. 
1.2.2.1.3.6  CD4+  T cells in autoimmune diseases  
The definition of an autoimmune disease is pathogenic outcome by the recognition of self-
antigens by the adaptive immune-system [18]. In light of thymic selection, the etiology of 
most autoimmune diseases is unknown. There is immense evidence of multiple factors 
affecting the onset and duration of autoimmunity, including genetic variants, environmental 
factors and (prolonged) infection or tissue damage. On the immunological level, 
dysregulation of thymic selection would emerge as a starting point. However, the onset of 
autoimmune diseases usually does not occur until young adulthood. This would implicate 
other mechanisms, for which self-tolerance is broken. In view of this, regulatory T cells has 
been intensively studied [57]. Briefly, the conclusions to this day states that Tregs have 
demonstrated both plastic as well as instable phenotype in patients with autoimmune 
disorders, compared to healthy subjects. Dysregulation of Tissue resident Tregs have also 
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been implicated in autoimmune settings [57]. 
Within the scoop of this thesis, we have investigated samples from patients with Rheumatoid 
Arthritis (RA) and Multiple Sclerosis (MS). While many findings in autoimmune research 
demonstrate similar T cell dysregulation, the short subsequent comments will focus on the 
findings in these to diseases. 
RA is characterised by systemic chronic inflammation of the joints, which results in 
degradation of cartilage and bone tissue. A number of cells from the immune system, most 
prominently T lymphocytes, infiltrate the synovial fluid of the joints, fuelling the chronic 
inflammation through constant expression of pro-inflammatory chemokines. 
MS is caused by inflammation and demyelination of neurons in the brain and spinal cord. 
Both these diseases, as well as most other autoimmune diseases, has originally been thought 
to have Th1 skewing properties, although more recent research has demonstrated that Th17 
cells seem to play a role in the maintenance of these two (as well as other autoimmune) 
diseases. In RA, synovial fluid contains high levels of IL-17, but not of IFNγ [58]. In MS, IL-
17 has been demonstrated to negatively affect the integrity of the blood-brain barrier, as well 
as having Th cells co-expressing IFNγ and IL-17 [59]. 
Taken together, the research of autoimmune diseases has demonstrated that specific subsets 
of CD4
+
 T helper cells are key players in the ingoing inflammation, that regulatory T cells are 
impaired in these situations, that tissue resident T cells might be implicated in initiation of 
disease, and also that IL-6 signalling is involved in driving the inflammation. All these 
features are sufficiently reviewed elsewhere [57, 60-63]. It is, however, clear that the 
different lineages of CD4
+
 T cells matters greatly, and that ongoing studies and clinical trials 
are exploring ways of interfering in this part of the inflammation processes. 
1.2.2.1.4 CD8+ cytotoxic T lymphocytes 
CD8
+ 
cells are the key player, ditto subsequent effector cells, of the Th1-initiated cellular 
cytotoxic response, i.e. type 1 immunity. The naïve CD8
+
 T cells become activated through 
recognition of the antigen presented on a HLA class I molecule by an APC, a process called 
cross-presentation. The APC as well as T helper cells use chemotaxis to attract naïve CD8
+
 T 
cells to the lymph node for priming. The signalling molecules, such as chemokines, also 
greatly enhance the efficacy of the activation. The CD8
+
 T cells can also be helped in 
activation through direct contact with T helper cells via CD40-CD40L interaction [64, 65]. 
The primed CD8
+
 T cell proliferate and acquire cytotoxic ability by expression of effector 
molecules. Through chemotaxis, cytotoxic T cells (CTLs) find their way to appropriate tissue, 
where they partake in elimination of the target antigen. Their mechanism of action is through 
signalling molecules like IFNγ and tumour necrosis factor (TNF), among others, and through 
killing of target cells, by means of their main effector molecules granzyme B and perforin 
[64]. This perfect duo of proteins are secreted when the TCR recognize the peptide for which 
it was primed, presented on HLA I on any somatic cell. Simplified, secreted perforin creates a 
pore in the cell membrane where granzyme B can enter into the cytoplasm. Membrane 
disruption along with enzymatic activity of granzyme B induces apoptosis [64, 66]. The 
regulation of these two signature proteins have been investigated in mouse and human. The 
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human PRF1 gene (coding perforin) demonstrate regulation by DNA methylation in CD8
+
 T 
cells [67], implicating that stable expression of perforin occurs after demethylation at this 
locus. The GZMB gene, coding for granzyme B, is in mouse epigenetically regulated by 
histone modifications [68] but have only been studied in CD4
+
 cells for locus specific DNA 
methylation [69]. Nevertheless, these studies implicate that epigenetic regulation is highly 
involved in memory development and maintenance of CD8
+
 T cells. The overall (bigger 
picture) transcriptional and epigenetic regulation of CD8
+
 T cells is reviewed in [70, 71] and 
is not in the scoop of this thesis. 
 
1.2.3 Tumour immunology 
Cancer is an abnormal event where the cells of the human body transform and proliferate in 
an uncontrolled way. This is due to mutations that primarily affect the cell cycle, and has 
been thoroughly described in the literature, beautifully clarified by the famous “hallmarks of 
cancer” [72]. Throughout a lifespan of a human, mutations inevitably arise and therefore 
exquisite ways to identify and protect the body against cancer has been developed throughout 
evolution. Protein-altering mutations are promptly discovered by circulating leucocytes, such 
as macrophages and NK cells, exerting immunosurveillance, through e. g. abnormal peptides 
presented on MHC I molecules. When abnormalities are recognised the innate immune cells 
eliminate the transformed cells, as well as secrete pro-inflammatory signalling molecules, 
such as IFNγ, to recruit dendritic cells (DCs). DCs migrate to LNs to involve T lymphocytes 
and thus the adaptive immune system is engaged in the process of tumour elimination. In 
order for the tumour to survive this elimination phase, further properties have to be 
developed. Tumours successful in continues growth maintain proliferation, while the adaptive 
immune cells keep the outgrowth in check. For the tumour to propagate further, more 
aggressive features have to be acquired. These properties, called immune escape, involve 
expressing immunosuppressive signalling molecules, such as TGFβ and inhibitory cell 
surface markers, such as PD-L1. Tumours also recruit immunosuppressive cells, such as 
Tregs and myeloid-derived suppressor cells (MDSC) to transform the surrounding milieu. All 
these new properties inhibit the immune response, despite the fact that the adaptive immune 
response may have antigen specificity and reside in the surrounding lymph nodes. This last 
stage, immune escape, is a prerequisite for the tumour to evolve into a full-blown malignancy 
[73, 74]. 
Importantly, the tumour states summarized above is a simplified overview of solid tumours, 
and is not translatable to tumours derived from lymphoid cells, such as lymphomas. 
In the last few decades, the potential of using the endogenous immune response in the battle 
towards cancer has been successfully explored. Opposite of chemotherapy and radiation, 
which primary goal was to eliminate rapidly growing cell populations, immunomodulatory 
strategies aim to block the immunosuppressive signals by the tumour and (re-)stimulate the 
silenced immune responses already present in the patient. The use of so called check-point 
inhibitors towards CTLA-4 and PD-1/PD-L1 has demonstrated a remarkable response (10-
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35%). Several other blocking antibodies are currently being developed to minimize the 
tumour derived immunosuppressive effect. It is, however, important to point out that far from 
all patients respond to these treatments, and that there is no or poor pre-treatment assessment 
to elucidate which patients will be responders [75]. Nevertheless, we are only just starting to 
grasp the full potential of our own immune system. 
Another method is adoptive cell therapy (ACT), which in the early 2000s’ presented 
promising results. It was based on re-infusion of extracted and in vitro expanded T cells, 
derived from tumour or lymph node. Although somewhat successful, there was great inter-
patient differences in success rate [76]. 
A newcomer on the ACT scene are the chimeric antigen derived T cells (CAR T cells). This 
is a development of the adoptive cell transfer, since autologous T cells are the starting 
material. Simplified, patient derived T cells are transfected with an engineered B cell receptor 
containing a kinase signalling construct to promote activation upon recognition of surface 
antigen. This therapy has been successful in liquid tumours, such as CD19
+
 B cell leukemia. 
Its effect on solid tumours has, however, yet to be further explored [77, 78]. 
Collectively, the immune system plays an important role in cancer development, and is a 
promising target and tool in new treatment strategies. 
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2 AIM 
The overall aim of this thesis was to investigate DNA methylation at specific loci as a method 
for interpretation of the direction of the immune responses in clinical settings. 
 
Paper I 
To examine DNA methylation in the IL17A locus and to design a DNA methylation assay to 
investigate the whole CD4
+
 T lymphocyte population for lineage commitment. 
Paper II 
To study the CD4
+
 T cell response in urinary bladder cancer using DNA methylation to 
establish methylation patterns and correlate with clinical outcome. 
Paper III 
To investigate the cytotoxic properties of tumour infiltrating CD8
+
 cytotoxic T lymphocytes 
in urinary bladder cancer. 
Paper IV 
To scrutinize the involvement of DNA methylation in glucocorticoid receptor gene NR3C1 in 
clinical outcomes after major surgical interventions. 
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3 METHODOLOGICAL CONSIDERATIONS 
Here follows brief comprehensive descriptions of selected methods used in this thesis, along 
with comments with regards to their applications herein. Detailed information is found in the 
papers, respectively. 
3.1 HUMAN TISSUE SPECIMENS 
All papers within this thesis contain research experiments conducted on human tissues. To a 
great extent, the samples have been processed immediately after retrieval, to minimize the 
risk of introducing errors by unnecessary interfering with the tissues. 
3.1.1 Peripheral blood (Paper I-IV) 
Patient blood was collected in heparin tubes, and processed for PBMC extraction and 
subsequent methods as fresh samples in paper I-III. In paper IV whole blood was frozen in 
RLT buffer for later processing. For healthy donors, blood was either collected in heparin 
tubes or as whole blood-derived leukocyte enrichments (buffy coats), and processed as fresh 
samples. 
3.1.2 Synovial fluid (paper I) 
The specimens was extracted from knee joints and processed for CD4
+
 T cell extraction. 
3.1.3 Lymph nodes and tumour tissue (paper II-III) 
During surgical procedures, specimens were collected in chilled serum-free medium and 
processed for cell extractions immediately after retrieval. 
It would have added great value to have absolute number of cells from each tissue, however, 
due to technical and surgical reasons, it was impossible to interpret the number of cells and 
correlate in-between patients. For lymph nodes, each node detected was divided between 
research studies and clinical evaluation by pathologist. The tumour tissues obtained are 
largely macroscopically diverse, in density and size, and the cell count from blood is not only 
dependent on volume, but also chemotherapy and possibly other clinical interventions 
unknown to us. 
3.2 CELL SORTING 
Paper I-III features sorted CD4
+
 and CD8
+
 T cells as a readout to investigate the course of the 
adaptive immune response. CD3
+
 cells were sorted from single cell suspensions derived from 
various tissues, through a magnetic antibody cell sorting method. The purified cells were then 
labelled with anti-CD4 and/or anti-CD8 fluorescent antibodies and sorted through flow 
cytometry. Although this two-step sorting strategy decreases the final yield, it was required to 
achieve desired purity of the final population from tissues other than peripheral blood. 
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3.3 DNA METHYLATION ANALYSIS 
In order to investigate DNA methylation, extracted DNA was bisulfite converted. Treating 
DNA with sodium bisulfite makes all the cytosine (C) not carrying a methyl group convert 
into uracil (U) (which during PCR is translated into thymine (T)). When performing 
sequencing the only Cs left are those which were originally methylated. This treatment does, 
however, make the DNA less stable and more fragile. It also greatly complicates the process 
of primer design for downstream applications. 
3.3.1 Sanger sequencing (paper I and III) 
This method is based on random blunt termination of amplification during PCR reaction, 
through incorporation of fluorescently labelled dideoxynucleotides (ddNTPs). The PCR 
products is then sorted by size through (capillary) gel electrophoresis and sequence is 
decoded by fluorescence, differentiated by four different colours corresponding to the four 
bases A, T, C and G respectively. 
When wanting to investigate a locus on a single cell level, a normal PCR is run and the 
amplicons are cloned into plasmids and transformed into bacteria. After culturing bacteria in 
medium they are plated on agar dishes. Individual clones from these dishes theoretically 
represents one single original PCR amplicon, derived from one single cell. By selecting a 
sufficient number of clones and proceed with sequencing it is possible to investigate the 
original cell population, from which the DNA was obtained, on a single cell level. 
The Sanger sequencing method can render a sequencing size up to ~800 base pairs, 
depending on the PCR amplicon size. However, for bisulfite sequencing the amplicon size is 
greatly reduced due to instability of bisulfite converted DNA. 
3.3.2 Bisulfite pyrosequencing (Paper II and III) 
A locus specific PCR is carried out, where one of the primers has been biotinylated. 
Following denaturation and clean-up procedure of the PCR product, a sequencing primer is 
annealed to the single stranded, biotinylated strand from the PCR product. The sequencing 
reaction is then performed by releasing one dNTP at a time. If the nucleotide is incorporated 
ATP is released to catalyse the luciferase reaction, leading to a light signal directly 
proportional to the number of incorporated nucleotides. The left-over nucleotides are then 
degraded before a new nucleotide is added. The dispensation order of the nucleotides is based 
on a pre-set, target sequence where a CpG site, and a possible methylated C, is evaluated by 
adding the nucleotides C and T. The relative intensity of the C and T signals will give the 
methylation percentage at that particular site. To this end, bisulfite pyrosequencing can be 
used to evaluate the proportion of methylation in a multi-cell sample. In this thesis 
pyrosequencing is used to establish the percentage of methylation in loci that have previously 
been investigated at a single cell level, and in a cell type specific manner. This allows for 
interpretation on a cell population basis. 
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3.3.3 Methyl sensitive Single Nucleotide primer extension (MS-SNuPE) 
(paper I) 
This method can be utilized when investigating methylation at a single CpG site. Briefly, a 
sequencing primer is designed to stretch to the base right before the C to be evaluated. A 
mixture of di-deoxyNTP is added to the previously performed locus specific PCR product for 
a single nucleotide extension and termination of elongation. The ddNTPs are coupled to 
fluorescent molecules to distinguish between the different nucleotides. The product is 
analysed by capillary gel electrophoresis, exiting the fluorescence and thereby revealing the 
incorporated nucleotide. The result discloses the ration between C to T fluorescence. In paper 
I this method is used on multiple sites, separated by different sizes of site specific sequencing 
primers. This allows for multiple site analyses in one read, although all previous steps need to 
be individually executed. 
3.4 CELL CULTURES WITH 5-AZA-CYTIDINE (5-AZA) (PAPER I AND III) 
5-aza is a nucleoside analogue that, after uptake of the cell, is metabolised into the nucleotide 
5-aza-2-deoxycytidin-thriphosphate and can subsequently be incorporated into DNA during 
replication as a substitute for cytosine [79, 80]. This random substitution leads to a covalent 
binding of DNMT1 to the DNA, and hence the DNA methylation is discontinued. By adding 
5-aza to in vitro cultures of proliferating cells it is possible to investigate downstream effects 
of random demethylation. Using cells that are naturally negative for the gene expression of 
interest might, upon proliferation, randomly begin to express the gene. This indicate the 
involvement of DNA methylation in regulation of the gene expression. It does not, however, 
convey if the outcome of 5-aza treatment has a direct effect on DNA methylation on the 
specific gene, or if it is indirect, through other genes that were demethylated. Hence, this is an 
indirect method of proving the involvement of DNA methylation on gene expression. 
3.5 ETHICAL CONSIDERATIONS 
The research in this thesis was conducted using a number of human tissues, all donated by 
patients and healthy volunteers. All tissues collected from patients were taken during clinical 
procedures, and all were approved by local ethical board (see papers for detailed 
information). Apart from blood and synovial fluid, that was taken in addition to clinical 
sampling, all other samples were extracted from the patient regardless of inclusion in our 
research. All patients have been well informed according to guidelines and appropriate ethical 
permissions are referred to in respective paper. For healthy donors, the same guidelines of 
informed consent apply, and the buffy coats, retrieved from voluntary blood donors are also 
an unused product of the blood components used by the clinic. 
To this end, I consider no additional harm has been inflicted, and I feel confident that this 
research stand on solid ethical ground. 
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4 RESULTS AND DISCUSSION 
The common denominator of my research was to use locus specific DNA methylation as a 
predictive indicator of the direction of immune response and of stable phenotype. The 
rational for this is that many genes can be transiently transcribed, with subsequent mRNA and 
protein expression. Hence, the time of measurement, the exact occasion that one retrieves and 
analyse the sample and the stage the overall biological process is in, has great effect on the 
levels of these molecules. On the contrary, DNA methylation is a stable modification that is 
only affected by active cell faith decisions during the course of a cells life [81]. 
The choice of gene to investigate in order to be able to draw conclusions on cell lineage, cell 
functionality or prediction of immune reaction is therefor of outermost importance. These 
features have to be investigated thoroughly, to establish the DNA methylation’s specific 
connection to features. It is important however, to realise that these characteristic measures 
reflect the attributes researchers have decided to name and label as separate, individual traits, 
setting one population apart from another, or on the other hand, putting all cells as equals. 
Although this has been thoroughly studied in most areas discussed within this thesis, it is not 
for me to say that these divisions are rock solid, and a 100% true at all times. With this in 
mind I will discuss the results of my work, in a somewhat fused, comprehensive context. 
 
4.1 THE TH17 LINEAGE 
In paper I we sought to design an epigenetic method to investigate the lineage distribution of 
CD4
+
 T cells. In order to do so, we first demonstrated that the IL17A locus could define Th17 
lineage. The in vitro protocols for generation of Th17 cells from naïve CD4
+
 T cells were not 
optimal (paper I, Figure 3B-C) when this research was performed, hence the Th17 cells 
analysed for DNA methylation in our paper derived from primary in vivo differentiated cells, 
present in peripheral blood. 
The methylation percentage of our sorted IL-17A
+
 cells is not irrefutable, and in hind sight I 
am convinced that the cells we sorted were contaminated in a number of ways. Firstly, the IL-
17A positive gate was unnecessarily generous. Secondly, the cells derive from over-night 
stimulated bulk CD4
+
 T cells from peripheral blood, which could give rise to a small portion 
of transient expression of IL-17A [82]. Thirdly, the gating strategy for sorting does not 
feature an exclusion gate for IFN-γ expression, which means that the cells sorted could 
possibly also contain a fraction of the reported Th1/Th17 cell subset. This, however, only 
support our conclusion that DNA methylation is a better way of defining CD4
+
 T cell 
lineages, as compared to protein expression. 
Newer studies on human Th17 cells have fortified our initial findings concerning DNA 
methylation being predictive of lineage commitment [42, 83]. Furthermore, it has been 
demonstrated that the non-classic Th1 cells (described in a number of papers with clinical 
settings) [84-87] derive from Th17 cells, as demonstrated by their demethylation in signature 
loci such as IL17A [42]. The non-classic Th1 cells are not in our sorted cell fraction, since 
 18 
they have lost their IL-17A expression. These recent findings demonstrate a more flexible 
phenotype of the Th17 lineage, resulting in the immunological community becoming more 
liberal in their view on Th17 cells. In light of these new discoveries, the population we refer 
to as Th17 cells (based on DNA demethylation) should instead be referred to as Th17 derived 
cells (paper II). Consequently, this has to be taken into consideration for future analysis of 
IL17A DNA methylation. Nevertheless, since we do not aim to show the activity of the 
immune system, but merely the skewing, suggesting what direction the adaptive immune 
response has taken, DNA methylation is still a valid method for these means. Thus, the 
methylation loci presented within this thesis still holds the appropriate information (Figure 2), 
even when considering the non-classic Th1 cells. The new knowledge on these cells, 
regarding the plasticity properties they hold [42, 88], only add further dimensions in how 
treatments could be designed. 
 
Figure 2. The CD4
+
 T cells and their lineage specific genes employed in this thesis. The 
demethylation is depicted through empty “lollipops” on a DNA helix. The picture conveys the 
lineage “snap-shot” we acquire through the DNA methylation analysis perform. The non-
classic Th1 cells demonstrate demethylation in IL17A locus, but the IFNG locus is yet to be 
investigated. 
 
4.2 CD4+ TH CELL LINEAGES IN AUTOIMMUNE DISEASES 
In order to implement our method “Epigenetic Immune Lineage Analysis” (EILA) we 
examined clinical samples from patients suffering from rheumatoid arthritis (RA) or multiple 
sclerosis (MS). The classic assumption on autoimmune disease is that the immune system is 
skewed towards a Th1 lineage and potential lack of, or dysfunctional Tregs [30, 32]. This is 
in accordance with our results (paper I figure 4A) where there is a higher FOXP3 methylation 
profile in circulating CD4
+
 T cells from RA patients, compared to healthy controls. 
Furthermore, comparing paired patient samples we demonstrate that Th cells from synovial 
fluid have a lower methylation in IFNG and FOXP3 compared to corresponding cells in 
peripheral blood. More recent investigations, demonstrate that non-classic Th1 cells 
constitute a significant proportion of the CD4
+
 T cells in synovial fluid from RA patients, 
although on a protein level [89]. This is consistent with part of our cohort, where four patients 
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displayed demethylation in IL17A, without corresponding mRNA expression (Paper I Suppl. 
Figure 3). It would have been of immense interest to investigate the epigenetic status of 
IL17A in the cells from the paper from Basdeo et al [88, 89]. Overall, the patient cohort might 
be taken into consideration and should potentially be more carefully dissected, for further 
insight and clarification. 
When investigating peripheral blood derived Th cells from patients with MS the methylation 
levels were significantly lower in FOXP3 and IL17A compared to healthy donors. The 
patients treated with Natalizumab (α4-integrin blocking antibody, inhibiting extravasation of 
T cells) had a Th cell methylation profile like the healthy controls (paper I figure 5A). The 
discovery of Th17 cells being an important player in MS has since been further investigated 
and established, as reviewed in [59]. 
These results suggests that while patients with RA lean towards Th1 skewing, the MS 
patients have a more pronounced Th17 profile. More recent studies have, however, 
demonstrated Th1 and Th17, as well as non-classic Th1 cells in both these conditions, 
although different Th subsets seem to be involved in various stages of the diseases [84-87]. 
Of note, while RA patients was examined at the site of inflammation (joints) the samples 
from MS patients was restricted to peripheral blood. This in itself could potentiate for miss-
match in read out and hence, the results demonstrated in these two disease states might not be 
straightforward to compare. 
Our aim was to implement our method in a clinical setting, for proof of concept, and not dive 
deep into the pathogenesis of RA or MS as a specific disease. Accordingly, the examination 
of these two autoimmune diseases demonstrate that our method EILA is sufficient to make an 
accurate readout of the Th cell lineage proportions, and by extension the current direction of 
the adaptive immune system. 
 
4.3 THE EILA CALCULATION 
In paper I, we investigated the sorted CD4
+
 T cell population. Due to suboptimal purity, we 
were obliged to find a way of excluding the contaminating cells by other means. To solve 
this, we made rigorous studies on the contaminating cell population of monocytes, to 
determine their background noise to our readout. We then developed a calculation method 
based on these investigations. By combining the contamination percentage with the 
corresponding background noise, we could subtract the influence of the monocytes, as well as 
that of naïve CD4
+
 T cells. 
A number of years passed from us publishing paper I until I started to investigate the CD4
+
 T 
cell population in patients with urinary bladder cancer. During this time, the field of human 
CD4+ T cells expanded and the consensus of what were the true stable lineages changed. Not 
only were subsets proposed, such as Th22 and Th9, but there was also the division into tissue 
specific subtypes, such as Tfh cells. In the beginning of my research studies, the two isoforms 
of the surface protein CD45, were used to distinguish naïve CD4
+
 T cells 
(CD45RA
+
CD45RO
-
) from antigen experienced memory CD4+ T cells (CD45RA
-
 20 
CD45RO
+
). The RA/RO distinction was widely used until an effector subset, namely TEMRA 
was discovered and other markers were established to distinguish between the two RA
+
 
populations [90]. This new knowledge, in combination with the fact that the distribution of 
different memory subsets varies in tissues made me decide to discard of the calculation 
developed in paper I. This decision was made because the calculation takes the proportion of 
CD45RA
+
 cells into consideration and refers to this population as naïve. Worth pointing out 
is that all the initial studies made on the stable differentiated lineages (Th1, Th2, Th17 and 
Tregs) (Figure 2) that we base the data on in paper I is executed on cells derived from 
peripheral blood [36-38]. These papers must have included the CD45RA
+
 cells (TEMRA), and 
although they might not be a big proportion in the blood, when looking in other tissues, such 
as synovial fluid, LNs and tumour, it is hard to justify the use of this calculation. The 
methylation pattern is convincing in all the previous studies, and therefore I believe that the 
data presented herein is valid. 
This means, however, that the results presented in paper II is not a direct product of the 
method we developed in paper I, but a new interpretation of the DNA methylation results 
referred to, and presented in paper I. We have not performed any further examinations into 
what type of CD4
+
 memory cells are present in the different tissues. Hence, I cannot draw 
any conclusions as to what memory differentiation stage the cells are in. I can, however, 
make conclusions on what proportions of cells are stably committed to one or the other of the 
four lineages we have investigated. This is, in my opinion, sufficient to make interpretations 
on the skewing of immune response in the tissues investigated (regardless of number of cells, 
or proportion of naïve and memory cells). 
 
4.4 ON TISSUE DISTRIBUTION AND DIFFERENTIATION STAGES OF T 
LYMPHOCYTES 
In order to include the new knowledge of different memory stages of CD4
+
 T cells we could 
have added more surface markers to discriminate different subsets, especially TEMRA etc. 
Upon doing so, it would have been necessary to investigate possible differences in 
methylation pattern in-between these. This could potentially have been an interesting and 
highly informative study, had it shown any results. It is, however worth noticing that the 
investigations leading up to the loci studied herein did not take these subpopulations into 
consideration [27, 36, 37, 41, 91, 92]. The research my work is based on have demonstrated 
functional properties in correlation with methylation patterns and this is what we consider 
valid information for our investigation. 
One might also speculate in the solidness of this localization-based subdivisions. For one, 
there are 2-5% TRM cells in the blood of both patients and healthy controls (Paper III figure 
3A-B, and data not shown), even though the subdivision/classification is based on markers 
such as epithelial adhesive proteins, (including CD103) that potentially should retain the 
aforementioned cells at its local site. Also, the impact that the subdivision has on our data is, 
in my opinion, a mere demonstration of different types off effector capacity. It is important to 
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clarify that the localisation subdivision has demonstrated clear differences in effector abilities 
[93], but within all these subsets, the skewing of the adaptive immune system is still present. 
Hence, these are two different layers of adaptive immunity, and it only becomes interesting 
when scrutinizing the T cells in a specific contextual setting.  
 
4.5 USING DNA METHYLATION OF T CELLS TO INVESTIGATE IMMUNE 
RESPONSES IN URINARY BLADDER CANCER 
In paper II and III we had the opportunity to examine T cells from different tissues collected 
from patients suffering from urinary bladder cancer. In paper II we take advantage of the 
results in paper I to explore the CD4
+
 T cell distribution in and around the tumour 
microenvironment. We demonstrate the possibility to extract pure T cells from different 
tissues and conclude that overall greater lineage commitment is correlated with better 
prognosis. 
In paper III we instead investigate the CD8
+
 T cell pool to scrutinize the ability of 
cytotoxicity. Through previous studies, we identified perforin as being a key effector 
molecule suppressed by the tumour microenvironment [94]. Hence, we decided to further 
investigate the regulation of perforin in Tc cells. 
In CD8
+
 T cells, there is a significant lower level of perforin expression in tumour compared 
to blood, but the methylation in PRF1 is the same in blood and tumour (Paper III fig 2A). 
This suggests that the tumour infiltrating cells are currently less activated, and we speculate 
that this might reflect the effect of tumour immunosuppression (Paper III figure 2A and 2B). 
When dividing the tumour derived CD8
+
 T cells into memory subsets the methylation status 
reflects the protein expression (as seen in Paper III, Figure 5C and 5D). 
The TRM cells, the most prominent subset in the tumour, are more methylated in blood than in 
tumour (Paper III, figure 3E). TRM cells are also T-bet low, on a protein level, which indicates 
that although demethylated in PRF1, the PD-1 expression is probably a sign of exhaustion, 
rather than that of activation, in these TRM cells. This is also in line with the 
immunosuppressive environment. 
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Figure 3. DNA methylation in IFNG locus of CD4
+
 TILs reveals an increase in Th1 lineage 
at tumour cT stages ≥3. 
On another note, concerning the T-bet expression, we show that upon in vitro stimulation of 
CD8+ TILs, the expression of T-bet is reinstated (Paper III, figure 4C and 4D). This leads me 
to hypothesis that the CD8
+
 T cells retrieved from the tumour mainly are Tc1 cells. 
To link the data from paper II and III, I compared the results from CD8
+
 TRM TILs with the 
IFNG methylation data from CD4
+
 TILs, both sorted out at time of Tur-B and stratified on cT 
stage (Figure 4, and Paper III, figure 6). (IFNG demethylated cells are referred to as Th1 cells 
here onwards). In contrast to the TRM proportion, Th1 cells from TILs increase in tumours 
staged ≥3 (Figure 4). We believe that the difference in stage 2 and 3, being the invasion of the 
perivesical tissue, is of importance for this increase in (and possibly renewed) Th1 
differentiation (Figure 3), also seen at pT staging in paper II (Figure 6A). There was no 
change seen in the other three Th cell loci investigated when stratified for cT stage (data not 
shown). We speculate that the perivesical invasion, being another barrier breakage, is the 
cause of this increase. Since the same stage have the opposite effect for the TRM pool, I'm 
once again speculating that the subdivision based on localisation is highly context dependent, 
and that stage 2 to 3 transformation is a game changer. 
My interpretation of these results is that the subdivision of memory subsets based on 
localisation does not seem to define the phenotypical properties of the CD8
+
 T cell pool. 
Also, the (relative) number of cells should be considered; not just the proportions within the 
CD8
+
 T cell or CD4
+
 Th cell pool, but in the whole local tissue. 
The CD8
+
 subset increasing in the one patient with stage 3 tumour was TEMRA which only 
seems like an expected transition when the tumour moves out of the tissue in which the Tcs 
were once resident. 
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Figure 4. Trends in population proportions stratified on cT stage. TILs extracted from Tur-B 
specimens. Proportion of CD8
+
 TRM cells (orange) within the CD8
+
T cell pool decreases with 
higher cT stage, but the Th1 cells (blue) increase. Th1 cells defined as IFNG demethylated. 
Regardless of our findings in paper II and III, it is important to point out that we have not 
investigated the antigen specificity in our studies. Instead, we base our conclusions on tissue 
localisation. Hence, it is not straightforward to make assumptions that all lymphocytes found 
within or adjacent to the tumour are tumour-specific. However, it has previously been 
established that adjacent LNs holds tumour antigen-specific lymphocytes [95]. Moreover, we 
have convincingly demonstrated, in patient belonging to the same recruitment study, [94, 96] 
that cells derived from SNs can be activated and proliferated in vitro in response to 
autologous tumour homogenate. However, there has not yet been any epigenetic 
investigations on the CD4
+
 or CD8
+
 T lymphocytes following these proliferation 
experiments. 
When combining the findings in Paper II and III it is plausible that a Th1/Tc1 response is of 
major benefit for prognosis. These speculations have support in the literature [97, 98] and 
hence, our data only further reinforce this consensus. 
 
4.6 DNA METHYLATION AND GENOTYPE VARIATIONS IN NR3C1 IN 
STERILE INFLAMMATION COHORT 
In Paper IV we wanted to investigate the role of DNA methylation in the Glucocorticoid 
receptor gene NR3C1 in the clinical setting of post-surgical sterile inflammation. This 
condition is a well-known complication following major surgery [99]. The first line of 
treatment is immunosuppression by corticosteroids, but this has an uneven effect between 
patients. The high variability in responses to the drugs cannot be correlated to pre-surgical 
endogenous cortisol levels, nor to the level of GR expression in peripheral blood cells [100, 
101]. Hence, we hypothesised that the differences in response in-between patients could be 
due to differential methylation patterns in the NR3C1 gene. It has previously been established 
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that DNA methylation pattern in the 3kb CpG island within this gene is a product of early life 
events and that this imprinting has an impact on neurobehavioral outcomes later in life [102, 
103]. If our hypothesis was correct, the pre-operative blood samples should display a high 
variation of methylation level in this locus, as has previously been demonstrated [104], and 
that this would correlate to clinical outcome. This was however not the case. Instead, our 
small cohort of 24 patients showed no variation in methylation (Figure 5). Thus, the 
methylation levels did not reveal any differences in correlation to any clinical readouts of 
outcome/outcome parameters. 
 
Figure 5: Heat map of all 319 CpG sites in NR3C1 locus chr5:143402.505-143.405.805. 
Apart from the last CpG, all sites are demethylated. Every row is one patient, every column a 
CpG site. 
There could be a number of reasons for our lack of variable methylation levels. First, our 
cohort may not reflect a cross section of the general population, but is biased by the clinical 
implications, although pathologically different, for which they are enrolled in major surgery. 
Another important factor, is that the studies made on early-life imprinting is conducted in 
brain tissue. The disease states investigated are to a high extent also neuro-behavioural 
conditions. This makes me speculate that specific cell type is of immense importance when 
studying DNA methylation. Our rational for hypothesising that we would see differences in 
whole blood, was (apart from others demonstrating it in healthy donors [104]) that the GR is 
expressed by virtually all nucleated cells and since the sterile inflammation is systemic, the 
blood would be a natural tissue to use for readout in this setting. As it turned out, there was 
no variation in these pre-surgical samples, and it is hard to predict if sorted cell populations 
(e.g. neutrophils, which would stand for the major expansion upon acute inflammatory 
response) would have differential DNA methylation levels, compared to e.g. lymphocytes. It 
is, difficult to speculate to what extent this would have made a difference in our results. 
Nevertheless, investigations of DNA methylation should be carefully examined in dissected 
cell populations, and correlated to cellular and biological function, prior to establishing 
methods that can use DNA methylation solely to make conclusions. 
Despite our rejected hypothesis, we further analysed the sequence data obtained. By multiple 
factor analysis we first ruled out that any of the clinical parameters available to us had a great 
impact on our model. Worth mentioning is that two variables emerged from this; sex and 
benign disease. The first two dimensions, however, only accounted for 7,1 % and 6,7 %, 
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respectively, of the variance in the material. Hence we concluded that none of these 
parameters had the power to significantly skew the model. 
The multifactorial partial least square (PLS) regression based analysis integrated the whole 
sequence (recovered from the bisulfite sequencing) and correlated it to outcome, as defined 
by Clavien-Dindo Score. We identified four SNPs that had an impact on outcome. 
The SNPs discovered in our analysis have all previously been identified and two of them 
have been studied in various settings (Paper IV, table 2). Although investigated in clinical 
settings different from ours, it is clear that genotype in the NR3C1 gene has an impact on 
clinical implications [105-107]. 
Due to our small cohort, it is difficult to draw any conclusions on how these SNPs impact the 
outcome, but on the basis of our results, in coherence with other findings, it is likely that 
simple genotype investigations on a much larger cohort would be sufficient to make greater 
conclusions on clinical outcome, when it comes to post-surgical sterile inflammation. 
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Figure 6. An artistic summery of the basic routs the adaptive immune system can take. With 
three major adaptive arms, type 1, type 2 and type 3 immunity sufficiently explains the 
different courses of immune responses seen in health and disease. In the middle is the APC, 
connecting the innate and adaptive immune system.  
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5 CONCLUDING REMARKS 
The collected work in this thesis has used DNA methylation as a tool for readout of the 
(innate and adaptive) immune responses in different clinical settings, such as RA, MS, UBC 
and sterile inflammation. Although widely different in their manifestations, and underlying 
cause, these studies have helped to shed some light over the involvement of inflammation in 
these pathological states. In addition, the results presented herein demonstrate the possibility 
of using DNA methylation to interpret disease states, but also that it is of great importance to 
thoroughly investigate cell specific features. When properly scrutinized, simple assays could 
be developed and used for clinical assessments. 
In the autoimmune diseases RA and MS, we investigated the CD4
+
 T cell population in blood 
and synovial fluid. We conclude that in both of these autoimmune diseases, there seem to be 
a difference in immune response on an individual level, which possibly reflects differential 
cause and development. In the tumour setting, we demonstrate that an overall greater 
immunological response correlates with better prognosis. When it comes to patients 
developing sterile inflammation, we conclude that genotype investigations could be a way 
forward to elucidate individual reactions. 
A major strength with the studies within this thesis is that primary human cells were used 
throughout. No tampering of cells, such as in vitro stimulation and differentiation, was 
needed to conduct most of these investigations [108]. This means that the pattern seen in the 
cells from the respective tissues is a snapshot of the true clinical picture. Although solely 
using DNA methylation only tells part of, and not the full story of how active the immune 
system actually is at present, it conveys in what direction and to what extent the body is 
leading the response. 
My overall conclusions regarding the adaptive immune response is that the dissection into 
type 1, 2 and 3 immunity, as previously proposed by many, sufficiently depicts the overall 
immune responses mounted by the human body (Figure 6), and that DNA methylation can be 
used to interpret this. 
The future goal is to use the results presented herein, on an individual basis, to evaluate the 
patient’s probability of responding to treatment. Furthermore, these data should be taken into 
consideration upon development of new, cell-based immunotherapies, or immunomodulatory 
therapeutic approach. 
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6 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Alla celler i kroppen innehåller samma DNA. Trots det har vi hundratals olika typer av celler 
som ser helt olika ut och kan göra helt olika saker. Det beror på att även om alla celler 
innehåller samma information, som en stor handbok, läser olika celler olika delar av boken 
(se Figur 1, sida 1). Vilka “kapitel” som är tillgängliga att läsa är reglerat av Epigenetik; 
“ovanför genetiken”. Epigenetisk reglering är således det som gör DNA åtkomligt eller inte. 
Det finns olika nivåer av epigenetisk reglering. Vissa påverkar histoner, proteiner som rullar 
upp DNA på spolar, och på så vis omöjliggör avläsning av denna genetiska region. En mer 
specifik reglering av enskilda gener är DNA-metylering. Ofta finns det kluster av dessa 
metylgrupper i så kallade CpG-öar, och dessa utgör regulatoriska element. Genom tillförsel 
eller avlägsnande av metylgrupper från DNA-sekvensen kan uttrycket av gener kopplade till 
denna region regleras. I den här avhandlingen har jag studerat DNA-metylering i celler från 
immunförsvaret. 
Immunförsvaret är uppdelat i det medfödda och det adaptiva immunförsvaret. Medan det 
medfödda ger ett snabbt men ospecifikt immunsvar tar det adaptiva upp till en vecka på sig 
för att skapa ett immunsvar som perfekt känner igen patogenet. Patogen kan vara allt från 
bakterier, virus eller annan infekterande agent, men även cancerceller och ibland den egna 
vävnaden, vilket resulterar i autoimmuna sjukdomar. Olika hot ger skilda adaptiva 
immunsvar (se Bild 6, sida 26). 
I första arbetet sätter vi upp en metod för att studera olika T-hjälparceller för att kunna 
utvärdera i vilken riktning det adaptiva immunförsvaret är vridet. Genom att använda fyra 
gener som är specifika för vart och ett av flera olika potentiella immunsvaren analyserar vi 
celler från friska personer såväl som från patienter med reumatoid artrit och multipel skleros. 
Vår slutsats är att metoden fungerar bra och att det finns många individuella skillnader mellan 
patienter med samma diagnos. Det är en fördel att veta innan det bestäms vilken behandling 
som ska sättas in, men även för att följa hur behandlingen påverkar immunförsvaret. 
I det andra arbetet tittar vi på samma gener i T-hjälparceller i patienter med urinblåsacancer. 
Genom att undersöka T-hjälparceller från både blod, tumör och lymfkörtlar får vi en bättre 
bild av vad som händer i och omkring tumören. Vår slutsats är att de patienter som har större 
proportioner av sina T-hjälparceller vridna mot ett starkt immunsvar har en bättre prognos. Vi 
visar också att de patienter som svarar på behandlingen med cytostatika har ett starkare 
immunsvar än de som inte svarade på behandlingen. 
I det tredje arbetet fortsätter vi att studera samma patienter och material, men nu i cytotoxiska 
T-celler. Vår slutsats är att dessa celler är temporärt avstängda i tumörer, förmodligen till 
följd av att tumören sänder ut negativa signaler. Vi visar däremot att om vi ger ny stimulans 
till dessa cytotoxiska T-celler utanför kroppen, i laboratoriet, kan de aktiveras på nytt. Detta 
skulle kunna vara ett sätt att ta tillvara på de celler som redan finns i tumören och därmed 
förmodligen känner igen den som ett hot. Våra resultat pekar på att det skulle gå att behandla 
patienten med sina egna cytotoxiska T celler. Denna metod (kallad cellulär immunterapi) är 
tidigare utvecklad för ovan nämnda T-hjälparcellerna.  
I det fjärde arbetet undersöker vi istället alla celler i blod från patienter som senare 
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genomgick en stor bukoperation. En känd komplikation vid stora operationer är utvecklandet 
av en steril inflammation. Det är en inflammation som är orsakad av själva traumat som 
operationen innebär. Människor reagerar väldigt olika på dessa operationer och vissa 
patienter utvecklar en steril inflammation, trots att de behandlas likadant. Behandlingen som 
ges är kortison som har en immunhämmande effekt. Kortison binder till 
Glukokortikoidreceptorn (GR) som finns på nästan alla celler i kroppen. Genen som styr GR 
(NR3C1) är tidigare känd för att vara reglerad av DNA-metylering. Därför utredde vi om 
olika metyleringsmönster kunde vara orsaken till de varierande svaren på kortison-behandling 
mellan patienterna. Det visade sig att så inte var fallet. Däremot hittade vi fyra SNPs (single 
nucleotide polymorphims)som kunde påverka utfallet av den sterila inflammationen. SNPs är 
en typ av variationer i genomet där endast en nukleotid (bas) i DNA-sekvensen skiljer sig åt 
och finns i varierande grad hos befolkningen. Vi summerar att vår studie är för liten för att 
kunna dra långtgående slutsatser kring dessa SNPs på ett tillförlitligt sätt, men vi tror att det 
skulle gå att utreda vikten av dessa sekvens-variationer om en större grupp patienter 
inkluderades. 
Mina sammanfattande slutsatser är att det går att använda analys av DNA-metylering för att 
påvisa olika adaptiva immunsvar i specifika immunceller, vilket kan vara till stor hjälp inom 
sjukvården för att utvärdera prognos och hur bra kroppen svarar på behandling. Det går också 
att använda för att utveckla nya biologiska och immunologiska behandlingsmetoder. Däremot 
verkar det vara av stor vikt att titta på specifika celltyper, även när det gäller en gen som 
uttrycks i många celltyper. 
Jag hoppas att min forskning kan komma till användning för utvecklingen av behandlingar 
och diagnostiska metoder för framtida bruk inom sjukvården. 
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7 When we were young Adele 
8 Dancing on my own Robyn 
9 Downtown Petula Clark 
10 Fjäriln vingad syns på Haga Carl Michael Bellman 
11 Hey ya! Outcast 
12 Son of a preacher man Aretha Franklin 
13 Belle Sofia Källgren 
14 Pompeii Bastille 
15 Royals Lorde 
16 Firework Katy Perry 
17 Do the Hippogriff Weird Sisters 
18 Séra Séra Shakira 
19 Från Djursholm till Danvikstull Orup 
20 Good morning Baltimore Nikki Blonsky 
21 I gotta feeling The Black Eyed Peas 
22 Don’t stop me now Queen 
23 In the club Danny Saucedo 
24 Sanna Vänner Carola 
25 Underground Broder Daniel 
26 Pom pom Magnus Uggla 
27 More than words (Mer än snor) Extreme 
28 Graduation (Friends forever) Vitamin C 
29 Music Madonna 
30 Because you loved me Celine Dione 
31 Easy Silence Dixie Chicks 
32 Håll om mig hårt Panetoz 
33 Vart jag än går Stiftelsen 
34 Vart du än går Lisa Nilsson 
35 Pure shores All Saints 
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